August 2025
1. GROLL AH, Danziger-Isakov L, Gefen A, Fraser CJ, et al
   Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study.
   Antimicrob Agents Chemother. 2025 Aug 18:e0042025. doi: 10.1128/aac.00420.
   

   >> Share

   
   June 2025
2. ANDREANI J, Truffot A, Tilloy V, Jardin H, et al
   Long-range PCRs and next-generation sequencing to detect cytomegalovirus drug resistance-associated mutations.
   Antimicrob Agents Chemother. 2025 Jun 25:e0014125. doi: 10.1128/aac.00141.
   

   >> Share

   
   May 2025
3. GULDBAEK JM, Mariager T, Nielsen MD, Terkelsen JH, et al
   Distribution of ganciclovir in the porcine central nervous system.
   Antimicrob Agents Chemother. 2025;69:e0181524.
   

   >> Share

   
   October 2024
4. YANG W, Irwin A, Weerdenburg H, McWhinney B, et al
   Serum ganciclovir drug exposure in children receiving standard ganciclovir dosing.
   Antimicrob Agents Chemother. 2024;68:e0052524.
   

   >> Share

   
   
5. PONTHIER L, Franck B, Autmizguine J, Labriffe M, et al
   Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy.
   Antimicrob Agents Chemother. 2024;68:e0086024.
   

   >> Share

   
   April 2023
6. FACCHIN A, Benyoub N, Elie V, Magreault S, et al
   Limited Sampling Strategies to Predict Ganciclovir Exposure after Valganciclovir Administration and to Reduce Monitoring Constraints in Renal Transplant Children.
   Antimicrob Agents Chemother. 2023;67:e0159722.
   

   >> Share

   
   March 2023
7. SELBY PR, Heffernan AJ, Yeung D, Warner MS, et al
   Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients.
   Antimicrob Agents Chemother. 2023;67:e0155022.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share